Mikael Dolsten, President, Worldwide Research & Development of Pfizer, Discusses a Potential Combination with AstraZeneca
Question 1 –
As a scientist, what do you believe are the benefits of this potential transaction?
Question 2 –
What would be the potential benefits to healthcare providers globally with a combined Pfizer and AstraZeneca?
Question 3 –
What do you think of Pfizer's existing pipeline and what are your impressions of AstraZeneca's?
Question 4 –
Can you elaborate on what is going on in Pfizer's mid-stage pipeline?
Question 5 –
How do you respond to the criticism that AstraZeneca's highly innovative approach to R&D will suffer if this potential combination were to go through?
Story Post Date:
Monday, May 12, 2014